The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Abstract
Background: Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough. Methods: Three hundred and seventy-nine participants completed online surveys before and after a planned psychedelic experience. Items pertaining to emotional breakthrough were completed one day after the psychedelic experience, as were items comprising the already validated Mystical Experience Questionnaire and the Challenging Experience Questionnaire. Emotional breakthrough, Mystical Experience Questionnaire and Challenging Experience Questionnaire scores were used to predict changes in well-being (Warwick-Edinburgh Mental Wellbeing Scale) in a subsample of 75 participants with low well-being baseline scores (⩽45). Results: Factor analyses revealed six emotional breakthrough items with high internal consistency (Cronbach’s alpha=0.932) and supported our prior hypothesis that emotional breakthrough is a distinct component of the psychedelic experience. Emotional breakthrough scores behaved dose-dependently, and were higher if the psychedelic was taken with therapeutic planning and intent. Emotional breakthrough, Mystical Experience Questionnaire and Challenging Experience Questionnaire scores combined, significantly predicted subsequent changes in well-being ( r=0.45, p=0.0005, n=75), with each scale contributing significant predictive value. Emotional breakthrough and Mystical Experience Questionnaire scores predicted increases in well-being and Challenging Experience Questionnaire scores predicted less increases. Conclusions: Here we validate a six-item ‘Emotional Breakthrough Inventory’. Emotional breakthrough is an important and distinct component of the acute psychedelic experience that appears to be a key mediator of subsequent longer-term psychological changes. Implications for psychedelic therapy are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most studies that have used an emotion regulation perspective have focused more heavily on acute emotional engagement and breakthrough rather than on the ability to evaluate and challenge the validity of automatic cognitions and core beliefs during a psychedelic session (Close et al., 2020; Roseman et al., 2019; Thiessen et al., 2018).”
From Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca (2022) · cites this paper as Roseman et al., 2019
In the citing paper
“In 2019, Roseman published the eight-item Emotional Breakthrough Inventory (EBI), designed to assess the phenomenon of overcoming challenging emotions/memories, thereby experiencing emotional release while under the influence of psychedelics (Roseman et al., 2019).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Roseman et al., 2019
In the citing paper
“The EBI is scored on a VAS scale from 0 to 100 and has demonstrated good internal consistency (Roseman et al., 2019).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Roseman et al., 2019
In the citing paper
“scored a total of 80 out of 100 on the emotional break through inventory (21)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [21]
In the citing paper
“Naturalistic studies have suggested that greater experiences of an emotional breakthrough whilst under the influence of a psychedelic positively predict improvements in psychological wellbeing in non-clinical populations [53].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [53]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Coefficient Alpha and the Internal Structure of Tests
Cronbach, L. J. (1951) · Psychometrika · doi:10.1007/bf02310555 · Cited by 43,931
Convergent and discriminant validation by the multitrait-multimethod matrix.
Campbell, D. T., & Fiske, D. W. (1959) · Psychological Bulletin · doi:10.1037/h0046016 · Cited by 17,116
The Scree Test For The Number Of Factors
Cattell, R. B. (1966) · Multivariate Behavioral Research · doi:10.1207/s15327906mbr0102_10 · Cited by 13,554 · cited 3×
“Modern phenomenological analyses (Belser et al., 2017; Gasser et al., 2014; Watts et al., 2017) and therapists’ accounts (Bonny and Pahnke, 1972; Cohen, 1959; Crocket et al., 1963; Eisner and Cohen, 1958; Fisher, 2015; Grof et al., 1980; Jensen, 1963; Katzenelbogen and Fang, 1953; Leuner, 1961;…”
BackgroundThe Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., Parkinson, J., Secker, J., & Stewart-Brown, S. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-63 · Cited by 5,031 · cited 2×
“The WEMWBS (Tennant et al., 2007) was designed to measure the psychological well-being of a population.”
BackgroundMethodGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…in determining long-term responses to psychedelics (Bogenschutz et al., 2015; Dakwar et al., 2014; Erritzoe et al., 2018; GarciaRomeu et al., 2014; Griffiths et al., 2016; Johnson et al., 2016; Klavetter and Mogar, 1967; Kurland et al., 1972; MacLean et al., 2011; O’Reilly and Funk, 1964; Pahnke…”
BackgroundViolin Plots: A Box Plot-Density Trace Synergism
Hintze, J. L., & Nelson, R. D. (1998) · The American Statistician · doi:10.1080/00031305.1998.10480559 · Cited by 1,802 · cited 1×
“See violin plots (Hintze and Nelson, 1998) of EBI, MEQ and CEQ in Figure 1.”
MethodRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 1×
“…et al., 2016; Johnson et al., 2016; Klavetter and Mogar, 1967; Kurland et al., 1972; MacLean et al., 2011; O’Reilly and Funk, 1964; Pahnke et al., 1970; Richards et al., 1977; Roseman et al., 2017; Ross et al., 2016) and see Stace (1960) for some classical texts relevant to the mystical experience.”
BackgroundGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 5×
“…et al., 2018; Hyde, 1960; Lasagna, 1963; Leary et al., 1963; Studerus et al., 2012) that context is an essential component of the psychedelic model (Carhart-Harris et al., 2017b; Hartogsohn, 2017; Leary et al., 1963) and that if one wishes to promote a positive therapeutic response to a…”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 16
- Abramson HA, 1960, The Use of LSD in Psychotherapy: Transactions
- Barrett FS, 2018, Int Rev Psychiatry, 1
- Belser A (2016) Real, Relational, and Embodied: The First Qualitative Study of Patient Experiences of Psilocybin-Assisted Psychotherapy. In: Interdisciplinary Conference on Psychedelics Research (ICPR), 6 June 2016. Amsterdam. Youtube–Available at: https://www.youtube.com/watch?v=DUYDjV8lQxo
- Breuer J, 1895, Studies on Hysteria
- Dittrich A, 1975, Z Klin Psychol Psychiatr Psychother, 23, 12
- Fisher FM, 2015, Therapy with Substance: Psycholytic Psychotherapy in the Twenty First Century
- Grof S, 1980, LSD Psychotherapy (The healing potential of psychedelic medicine)
- Huxley A, 1945, The Perennial Philosophy
- Hyde RW, 1960, Dynamics of Psychiatric Drug Therapy, 297
- Johnson MW, 2016, Am J Drug Alcohol Abuse, 1
- Katzenelbogen S, 1953, Dis Nerv Syst, 14, 85
- Kurland AA, 1972, J Thanatol, 2, 644
- Leuner H, 1961, Hallucinogenic Drugs, 67, 67
- Loizaga-Velder A, 2013, MAPS Bull, 23, 36
- Pahnke WN, 1969, Curr Psychiatr Ther, 9, 144
- Sandison R, 1955, Nurs Mirror, 100, 1529
Cited by
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Self-citationPsychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Increased global integration in the brain after psilocybin therapy for depression
(2022) · doi:10.1038/s41591-022-01744-z · Cited by 445
Self-citationAgin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
“, 2016) or emotional breakthrough experiences (Roseman et al., 2019), are more influential in explaining long-term changes of psilocybin-assisted psychotherapy.”
BackgroundInfluentialPsychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Metadata
- Authors
- Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Roseman, Leor
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2019-07-11
- Volume
- 33
- Issue
- 9
- Pages
- 1076-1087
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2962285119
- Cited by
- 413
- References
- 65
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 87 · 2023: 72 · 2022: 52 · 2021: 37 · 2020: 20
- FWCI
- 31.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wavepaths
- Ad Astra Chandaria Foundation
- imperial college london
- Alex Mosley Charitable Trust
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic therapy, mystical experience, well-being, psychological change, treatment planning
- MeSH terms
- Adult, Emotions, Female, Hallucinogens, Humans, Male, Mysticism, Psilocybin, Surveys and Questionnaires
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. https://app.cochat.ai/papers/10.1177/0269881119855974
- The paper
- Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology. https://doi.org/10.1177/0269881119855974
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.